ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026, notifying the company of its failure to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. Due to a prior 1-for-10 reverse stock split on August 12, 2025, the company is ineligible for a 180-day compliance period. The company intends to appeal the determination via a hearing before the Panel. ENvue Medical, Inc. operates in the medical technology industry and develops medical devices for skin-related conditions.
